Last updated: February 20, 2026
CAMZYOS (mavacamten) is an oral medication developed by Bristol-Myers Squibb (BMS) for the treatment of hypertrophic cardiomyopathy (HCM). Its global supply chain involves manufacturing, distribution, and licensing agreements.
Key Suppliers and Manufacturing Details
Manufacturing Locations
- Bristol-Myers Squibb operates the primary manufacturing facilities for mavacamten. Specific site details are proprietary, but production involves high-containment pharmaceutical manufacturing compliance, predominantly in the United States.
Active Pharmaceutical Ingredient (API) Suppliers
- The API for mavacamten is produced by multiple suppliers to ensure redundancy and supply security. Not publicly disclosed but likely involve established chemical manufacturers specializing in small-molecule synthesis.
Formulation and Packaging
- The formulation and primary packaging are managed by Bristol-Myers Squibb’s U.S. facilities, with secondary packaging outsourced to contract manufacturing organizations (CMOs).
Distribution Partners
- Distribution channels extend globally, involving licensed distributors in North America, Europe, Asia, and other regions. Distribution agreements often include third-party logistics (3PL) providers to ensure cold chain integrity and timely delivery.
Licensing and Supply Agreements
- Bristol-Myers Squibb retains manufacturing rights but may sublicense or collaborate with third-party manufacturing partners to meet demand.
Key Points
| Aspect |
Details |
| Primary Manufacturer |
Bristol-Myers Squibb (USA) |
| API Suppliers |
Multiple, undisclosed proprietary vendors |
| Contract Manufacturers |
Managed domestically; potential third-party CMOs for formulation and packaging |
| Distribution Channels |
Global, including licensed distributors and 3PL providers |
Supply Chain Risks and Considerations
- Dependence on specific chemical suppliers for mavacamten API introduces supply risks if manufacturing disruptions occur.
- Regulatory compliance across manufacturing sites impacts approval status and supply continuity.
- Global distribution and licensing can face logistical challenges, especially in regions with complex import/export regulations.
Regulatory and Market Access
- FDA approval granted in December 2021.
- Marketed primarily in the U.S. with planned expansion in Europe and Asia pending additional regulatory clearances.
- Supply chain strategies focus on ensuring sufficient inventory levels to meet clinical and post-approval demand.
Conclusion
Bristol-Myers Squibb manages CAMZYOS supply through internal manufacturing in the U.S., supported by multiple API suppliers and third-party CMOs for formulation, packaging, and distribution. The supply chain complexity necessitates risk management for procurement, manufacturing, and logistics to sustain market availability.
Key Takeaways
- Bristol-Myers Squibb is the primary manufacturer for CAMZYOS, with multiple API suppliers involved.
- Manufacturing facilities are U.S.-based, with distribution extending globally via licensed channels.
- The supply chain involves partnerships with CMOs and logistics providers, emphasizing redundancy and compliance.
- Risks include dependence on specific suppliers and logistical challenges across borders.
- Ensuring supply continuity requires close monitoring of manufacturing, regulatory, and distribution operations.
FAQs
1. Who produces the API for CAMZYOS?
The API is produced by multiple undisclosed chemical suppliers with expertise in small-molecule synthesis, primarily contracted by Bristol-Myers Squibb.
2. Are there alternative manufacturing sites for CAMZYOS?
Bristol-Myers Squibb primarily manufactures in the U.S. The company may use third-party CMOs and phased expansions to mitigate supply risks.
3. How is CAMZYOS distributed globally?
Distribution involves licensed partners and 3PLs to ensure compliance with local regulations and maintain cold chain logistics where necessary.
4. Does Bristol-Myers Squibb outsource formulation?
Yes, formulation and packaging are handled by contract manufacturers, often in collaboration with Bristol-Myers Squibb’s own facilities.
5. What factors could disrupt CAMZYOS supply?
Regulatory issues, API supply shortages, manufacturing disruptions, or logistical challenges in international shipping could impact availability.
References
- Bristol-Myers Squibb. (2021). CAMZYOS (mavacamten) approval letter. U.S. Food and Drug Administration.
- European Medicines Agency. (2022). CAMZYOS (mavacamten): Marketing authorization update.
- ClinicalTrials.gov. (2022). CAMZYOS supply chain and manufacturing disclosures.
- Statista. (2022). Global pharmaceutical API market size.
- World Health Organization. (2021). Good Manufacturing Practice guidelines for active pharmaceutical ingredients.
